Efficacy of resveratrol supplementation against non-alcoholic fatty liver disease: a meta-analysis of placebo-controlled clinical trials
C Zhang, W Yuan, J Fang, W Wang, P He, J Lei… - PLoS …, 2016 - journals.plos.org
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease with
rising prevalence. Increasing evidence has demonstrated that resveratrol, a dietary …
rising prevalence. Increasing evidence has demonstrated that resveratrol, a dietary …
Effects of resveratrol supplementation in patients with non-alcoholic fatty liver disease—a meta-analysis
K Jakubczyk, K Skonieczna-Żydecka, J Kałduńska… - Nutrients, 2020 - mdpi.com
Non-alcoholic fatty liver disease (NAFLD) is regarded as one of the most common liver
pathologies in many societies. Resveratrol, as a phenolic compound with powerful …
pathologies in many societies. Resveratrol, as a phenolic compound with powerful …
[PDF][PDF] Resveratrol supplementation in patients with non-alcoholic fatty liver disease: systematic review and meta-analysis.
A Elgebaly, IAI Radwan, MM AboElnas… - … of gastrointestinal & …, 2017 - academia.edu
Background: Resveratrol is a potential treatment option for management of non-alcoholic
fatty liver disease (NAFLD) due to its anti-inflammatory, antioxidant properties, and calorie …
fatty liver disease (NAFLD) due to its anti-inflammatory, antioxidant properties, and calorie …
Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses
X He, Y Li, X Deng, X Xiao, J Zeng - Frontiers in Pharmacology, 2023 - frontiersin.org
Background: Resveratrol, a polyphenol found in various plants, is known for its diverse
bioactivities and has been explored in relation to nonalcoholic fatty liver disease (NAFLD) …
bioactivities and has been explored in relation to nonalcoholic fatty liver disease (NAFLD) …
Efficacy of resveratrol supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials
S Rafiee, H Mohammadi, A Ghavami, E Sadeghi… - … therapies in clinical …, 2021 - Elsevier
Background Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver
disease and refers to the accumulation of triglycerides in hepatocytes. Recent studies have …
disease and refers to the accumulation of triglycerides in hepatocytes. Recent studies have …
[HTML][HTML] Efficacy of resveratrol supplementation on liver enzymes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis
S Wei, X Yu - Complementary therapies in medicine, 2021 - Elsevier
Abstract Objective Randomized clinical trials (RCTs) examining the effects of resveratrol
supplementation on liver enzymes in non-alcoholic fatty liver disease (NAFLD) have …
supplementation on liver enzymes in non-alcoholic fatty liver disease (NAFLD) have …
Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease
S Heebøll, M Kreuzfeldt, S Hamilton-Dutoit… - Scandinavian journal …, 2016 - Taylor & Francis
Objective “The obesity epidemic” has led to an increase in obesity-related conditions
including non-alcoholic fatty liver disease (NAFLD), for which effective treatments are in …
including non-alcoholic fatty liver disease (NAFLD), for which effective treatments are in …
Hepatoprotective effects of resveratrol in non-alcoholic fatty live disease
S Tejada, X Capó, CM Mascaró… - Current …, 2021 - ingentaconnect.com
Background: Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of
chronic liver disease worldwide, directly related to the progressive increase in body weight …
chronic liver disease worldwide, directly related to the progressive increase in body weight …
Resveratrol does not benefit patients with nonalcoholic fatty liver disease
Background & Aims Nonalcoholic fatty liver disease (NAFLD), characterized by
accumulation of hepatic triglycerides (steatosis), is associated with abdominal obesity …
accumulation of hepatic triglycerides (steatosis), is associated with abdominal obesity …
The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo …
F Faghihzadeh, P Adibi, A Hekmatdoost - British Journal of Nutrition, 2015 - cambridge.org
Non-alcoholic fatty liver disease (NAFLD) is usually associated with insulin resistance,
central obesity, reduced glucose tolerance, type 2 diabetes mellitus and …
central obesity, reduced glucose tolerance, type 2 diabetes mellitus and …